Strategies for suppressing muscle atrophy in chronic kidney disease: mechanisms activating distinct proteolytic...

Area of Science:

• Biochemistry
• Cell Biology
• Nephrology

Background:

• Muscle wasting, characterized by loss of protein and lean body mass, is prevalent in chronic kidney disease (CKD) patients.
• The precise cellular mechanisms driving muscle atrophy in CKD remain largely undefined.
• Evidence suggests the ubiquitin-proteasome proteolytic system is activated in muscle under uremic and catabolic conditions.

Purpose of the Study:

• To elucidate the cellular mechanisms responsible for muscle atrophy in chronic kidney disease.
• To identify key molecular players and pathways involved in protein degradation in CKD-associated muscle wasting.

Main Methods:

• Investigated the role of the ubiquitin-proteasome system and caspase-3 in muscle protein degradation.
• Examined the impact of impaired insulin signaling and phosphatidylinositol 3-kinase (PI3K) activity on muscle atrophy.
• Utilized animal models of uremia and peritoneal dialysis patients.

Main Results:

• Caspase-3 initiates actomyosin and myofibril cleavage, evidenced by a 14-kDa actin fragment.
• Activation of the E3 ubiquitin-conjugating enzyme atrogin-1 is a critical step in stimulating the ubiquitin-proteasome system.
• Both caspase-3 and the ubiquitin system, including atrogin-1, are activated by suppressed phosphatidylinositol 3-kinase activity due to impaired insulin signaling.

Conclusions:

• Impaired insulin signaling, specifically reduced PI3K activity, triggers both caspase-3 and ubiquitin-proteasome system activation, leading to muscle wasting in CKD.
• Targeting strategies to prevent decreased PI3K activity or inhibit caspase-3 could offer novel treatments for preventing muscle wasting in CKD patients.